Charles N. York II Sells 4,370 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the transaction, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. This trade represents a 1.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN traded up $0.20 during midday trading on Friday, hitting $12.43. 758,249 shares of the company’s stock traded hands, compared to its average volume of 981,378. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.13 and a 1 year high of $18.07. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46. The firm has a fifty day moving average of $12.37 and a 200 day moving average of $13.47.

Wall Street Analyst Weigh In

DAWN has been the subject of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. Bank of America decreased their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Day One Biopharmaceuticals has a consensus rating of “Buy” and a consensus target price of $35.71.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at approximately $27,000. R Squared Ltd bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after acquiring an additional 1,002 shares during the period. Quest Partners LLC grew its stake in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after acquiring an additional 7,668 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after acquiring an additional 9,603 shares during the period. 87.95% of the stock is currently owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.